These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31489538)

  • 1. Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients.
    Berends SE; van Steeg TJ; Ahsman MJ; Singh S; Brandse JF; D'Haens GRAM; Mathôt RAA
    J Pharmacokinet Pharmacodyn; 2019 Dec; 46(6):543-551. PubMed ID: 31489538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevation of PRKCDBP, a novel transcriptional target of TNF-α, and its downregulation by infliximab in patients with ulcerative colitis.
    Kim JW; Kim HJ; Lee CK; Shim JJ; Jang JY; Dong SH; Kim BH; Chang YW; Chi SG
    Dig Dis Sci; 2014 Dec; 59(12):2947-57. PubMed ID: 25052149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis.
    Brandse JF; van den Brink GR; Wildenberg ME; van der Kleij D; Rispens T; Jansen JM; Mathôt RA; Ponsioen CY; Löwenberg M; D'Haens GR
    Gastroenterology; 2015 Aug; 149(2):350-5.e2. PubMed ID: 25917786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis.
    Olsen T; Rismo R; Gundersen MD; Paulssen EJ; Johnsen K; Kvamme JM; Goll R; Florholmen J
    Cytokine; 2016 Mar; 79():90-5. PubMed ID: 26775117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of treatment failure during infliximab induction therapy in inflammatory bowel disease patients based on pharmacokinetic and pharmacodynamic modeling.
    Kimura K; Yoshida A; Katagiri F; Takayanagi R; Yamada Y
    Eur J Pharm Sci; 2020 Jul; 150():105317. PubMed ID: 32205229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis.
    Fasanmade AA; Adedokun OJ; Ford J; Hernandez D; Johanns J; Hu C; Davis HM; Zhou H
    Eur J Clin Pharmacol; 2009 Dec; 65(12):1211-28. PubMed ID: 19756557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis.
    Brandse JF; Mathôt RA; van der Kleij D; Rispens T; Ashruf Y; Jansen JM; Rietdijk S; Löwenberg M; Ponsioen CY; Singh S; van den Brink GR; D'Haens GR
    Clin Gastroenterol Hepatol; 2016 Feb; 14(2):251-8.e1-2. PubMed ID: 26545802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis.
    Vande Casteele N; Khanna R
    Pharm Res; 2017 Aug; 34(8):1556-1563. PubMed ID: 28374338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.
    Su C; Salzberg BA; Lewis JD; Deren JJ; Kornbluth A; Katzka DA; Stein RB; Adler DR; Lichtenstein GR
    Am J Gastroenterol; 2002 Oct; 97(10):2577-84. PubMed ID: 12385442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis.
    De Vos M; Dewit O; D'Haens G; Baert F; Fontaine F; Vermeire S; Franchimont D; Moreels T; Staessen D; Terriere L; Vander Cruyssen B; Louis E;
    J Crohns Colitis; 2012 Jun; 6(5):557-62. PubMed ID: 22398050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis.
    Olsen T; Goll R; Cui G; Christiansen I; Florholmen J
    Cytokine; 2009 May; 46(2):222-7. PubMed ID: 19286392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis.
    Adedokun OJ; Xu Z; Liao S; Strauss R; Reinisch W; Feagan BG; Sandborn WJ
    Clin Ther; 2020 Jan; 42(1):157-174.e4. PubMed ID: 31982148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C.
    Magnusson MK; Strid H; Isaksson S; Bajor A; Lasson A; Ung KA; Öhman L
    J Crohns Colitis; 2015 Jan; 9(1):56-65. PubMed ID: 25518051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of clinical and endoscopic responses to anti-tumor necrosis factor-α antibodies in ulcerative colitis.
    Morita Y; Bamba S; Takahashi K; Imaeda H; Nishida A; Inatomi O; Sasaki M; Tsujikawa T; Sugimoto M; Andoh A
    Scand J Gastroenterol; 2016 Aug; 51(8):934-41. PubMed ID: 26888161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study.
    Viola A; Pugliese D; Renna S; Furfaro F; Caprioli F; D'Incà R; Bossa F; Mazza S; Costantino G; Fantini MC; Fiorino G; Alibrandi A; Orlando A; Armuzzi A; Fries W
    Dig Liver Dis; 2019 Apr; 51(4):510-515. PubMed ID: 30472389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
    Adedokun OJ; Sandborn WJ; Feagan BG; Rutgeerts P; Xu Z; Marano CW; Johanns J; Zhou H; Davis HM; Cornillie F; Reinisch W
    Gastroenterology; 2014 Dec; 147(6):1296-1307.e5. PubMed ID: 25173754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation.
    Magro F; Afonso J; Lopes S; Coelho R; Gonçalves R; Caldeira P; Lago P; de Sousa HT; Ramos J; Gonçalves AR; Ministro P; Rosa I; Vieira AI; Andrade P; Soares JB; Carvalho D; Sousa P; Meira T; Lopes J; Moleiro J; Dias CC; Falcão A; Geboes K; Carneiro F;
    EBioMedicine; 2017 Jul; 21():123-130. PubMed ID: 28629912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.